Home | Contact Us

NEWS AND EVENTS

 

 

 

PRESS RELEASES

2014

3/24/2014 - Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference
Read more
1/7/2014 - Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
Read more

2013

12/11/2013 - Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
Read more
10/15/2013 - Sutro Biopharma Presents Dual-Warhead Antibody Drug Conjugate at the World ADC Summit
Read more
1/31/2013 - Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
Read more
1/3/2013 - Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates
Read more

2012

12/18/2012 - Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies
Read more
10/24/2012 - Sutro Biopharma Expands Senior Management Team
Read more
5/8/2012 - Sutro Closes $16.5 Million Second Tranche of Series C Financing
Read more
1/7/2012 - Sutro Announces Newly Formed Scientific Advisory Board - Renowned Researchers James A. Wells, Ph.D., and James R. Swartz, Sc.D., to Guide Sutro’s Advancing Therapeutic Pipeline
Read more

2011

10/17/2011 - Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin.
Read more
5/19/2011 - Study Shows Sutro Biopharma’s Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals. Results Published in Biotechnology and Bioengineering Demonstrate that Cell-Free Production of a Biologically Active Human Cytokine Can be Scaled-up to Commercial Manufacturing Levels.
Read more Link to Article
1/7/2011 - Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel, Peptide-Based Therapeutics.
Read more

2010

12/8/2010 - Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer. Appointment Reflects Biopharmaceutical Company's Commitment to the Development of Novel and Biosuperior Protein Therapeutics.
Read more
11/17/2010 -Sutro Biopharma Secures $36.5 Million in Series C Financing.
Read more

2009

08/20/2009 - Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team.
Read more
06/09/2009 - Sutro Biopharma Adds to Extensive IP Portfolio with Two Newly Issued Patents and Two Patent Grant Notices. Covers the Only Cell-Free Synthesis Platform Applicable to Protein Discovery Through Production.
Read more
03/30/2009 - Sutro Biopharma Hits Major Technical Milestone, Reaching 100 Liter Scale for the Company’s Open Cell-free Protein Synthesis Technology. Milestone Triggers $15 Million Series B Financing.
Read more
01/12/2009 - William J. Newell Named Chief Executive Officer of Sutro Biopharma. Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer. Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco.
Read more